(Note: This is a unit offering with KTTA as the proposed symbol for the common stock and KTTAW for the warrants.) 

We are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. We believe that the current treatments for these disorders, such as depression, are inadequate and that conventional medicines have low success rates in long-term treatment. 

Our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability. We will particularly focus on the cross-talk between the immune system and brain disorders and how immune dysregulation affects central nervous system (CNS) function.

Our secondary operations are focused on providing business support services to anti-depression clinics in the UK and in the United States. Our operations in the UK will involve providing business support services to registered healthcare providers who will assess patients and, if appropriate, administer intravenous infusions of ketamine, and our operations in the United States will involve providing business support services to entities that furnish similar services to patients who personally pay for those services. Operations will initially take place across the United States and the UK through partnerships with healthcare companies, including Zen Healthcare and The IV Doc. 

*Note: The net loss figure is for the six months that ended June 30, 2021. 

(Note: Pasithea Therapeutics upsized its IPO unit offering at pricing on Sept. 14, 2021, to 4.8 million units, up from 2.9 million units, and priced the units at $5, the low end of its $5-to-$7 range, to raise $24 million.)